Established Stem Cell Model of Spinal Muscular Atrophy Is Applicable in the Evaluation of the Efficacy of Thyrotropin-Releasing Hormone Analog
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by the degeneration of spinal motor neurons. This disease is mainly caused by mutation or deletion of the survival motor neuron 1 (SMN1) gene. Currently, no effective treatment is available, and only symptomatic treatment can be provided. Our purpose in the present study was to establish a human SMA-derived induced pluripotent stem cell (SMA-iPSC) disease model and assay a therapeutic drug in preparation for the development of a novel treatment of SMA. We generated iPSCs from the skin fibroblasts of a patient with SMA and confirmed that they were pluripotent and undifferentiated. The neural differentiation of SMA-iPSCs shortened the dendrite and axon length and increased the apoptosis of the spinal motor neurons. In addition, we found activated astrocytes in differentiated SMA-iPSCs. Using this model, we confirmed that treatment with the thyrotropin-releasing hormone (TRH) analog, 5-oxo-l-prolyl-l-histidyl-l-prolinamide, which had marginal effects in clinical trials, increases the SMN protein level. This increase was mediated through the transcriptional activation of the SMN2 gene and inhibition of glycogen synthase kinase-3β activity. Finally, the TRH analog treatment resulted in dendrite and axon development of spinal motor neurons in differentiated SMA-iPSCs. These results suggest that this human in vitro disease model stimulates SMA pathology and reveal the potential efficacy of TRH analog treatment for SMA. Therefore, we can screen novel therapeutic drugs such as TRH for SMA easily and effectively using the human SMA-iPSC model. Significance: Platelet-derived growth factor (PDGF) has recently been reported to produce the greatest increase in survival motor neuron protein levels by inhibiting glycogen synthase kinase (GSK)-3β; however, motor neurons lack PDGF receptors. A human in vitro spinal muscular atrophy-derived induced pluripotent stem cell model was established, which showed that the thyrotropin releasing hormone (TRH) analog promoted transcriptional activation of the SMN2 gene and inhibition of GSK-3β activity, resulting in the increase and stabilization of the SMN protein and axon elongation of spinal motor neurons. These results reveal the potential efficacy of TRH analog treatment for SMA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ohuchi et al., 2006, first used SMA patient iPSC-derived motor neurons and astrocytes to show the role of the thyrotropin-releasing hormone analog for the treatment of SMA, which has been taken to clinical trials and showed the potential efficacy of this drug for the treatment of SMA [51].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of this technology in drug discovery has allowed the identification of many new compounds for the potential treatment of various diseases including Zika virus [66], SMA [51], as well as understanding cellular processes and developmental stages using genome editing strategies [72].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [51]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
A more efficient method to generate integration-free human iPS cells
Okita, K., Matsumura, Y., Sato, Y., Okada, A., Morizane, A., Okamoto, S., Hong, H., Nakagawa, M., Tanabe, K., Tezuka, K.-I., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1591 · Cited by 2,061
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Induced pluripotent stem cells from a spinal muscular atrophy patient
Ebert, A. D., Yu, J., Rose, F. F., Mattis, V. B., Lorson, C. L., Thomson, J. A., & Svendsen, C. N. (2009) · Nature · doi:10.1038/nature07677 · Cited by 1,441
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Directed differentiation of telencephalic precursors from embryonic stem cells
Watanabe, K., Kamiya, D., Nishiyama, A., Katayama, T., Nozaki, S., Kawasaki, H., Watanabe, Y., Mizuseki, K., & Sasai, Y. (2005) · Nature Neuroscience · doi:10.1038/nn1402 · Cited by 787
Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.01.009 · Cited by 741
The survival motor neuron protein in spinal muscular atrophy
Coovert, D. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.8.1205 · Cited by 714
Jackson, I. M. D. (1982) · New England Journal of Medicine · doi:10.1056/nejm198201213060305 · Cited by 674
Cited by
Vulnerability of Purkinje Cells Generated from Spinocerebellar Ataxia Type 6 Patient-Derived iPSCs
Ishida, Y., Kawakami, H., Kitajima, H., Nishiyama, A., Sasai, Y., Inoue, H., & Muguruma, K. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.026 · Cited by 123
“Cell Reports 17, 1482–1490, November 1, 2016 1487 (legend on next page) 1488 Cell Reports 17, 1482–1490, November 1, 2016 neurons derived from spinal muscular atrophy-specific iPSCs (Ohuchi et al., 2016).”
Human pluripotent stem cell–derived models and drug screening in CNS precision medicine
Silva, M. C., & Haggarty, S. J. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14012 · Cited by 83
Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
“SMA iPSC-derived neurons are not only used in the pathogenic investigation but also in therapeutic discovery.”
MethodInfluentialBarral, S., & Kurian, M. A. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00078 · Cited by 44
“…et al. (2015), Liu et al. (2015), Ng et al. (2015), Fuller et al. (2016), Heesen et al. (2016) and Patitucci and Ebert (2016) Sareen et al. (2012), Ohuchi et al. (2016) and Xu et al. (2016) Corti et al. (2012), Nizzardo et al. (2015) and Yoshida et al. (2015) et al., 2012); oligodendrocytes…”
Sabitha, K. R., Shetty, A. K., & Upadhya, D. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.12.025 · Cited by 60
“Reduced dendritic and axonal length with increased selective motor neuron death, a defect mimicking disease phenotype has been recapitulated in motor neurons generated SMA-iPSCs (Ebert et al., 2009; Chang et al., 2011; Ohuchi et al., 2016; Son et al., 2019).”
BackgroundInfluentialTherapeutic potential of stem cells for treatment of neurodegenerative diseases
Ahmadian-Moghadam, H., Sadat‐Shirazi, M., & Zarrindast, M. (2020) · Biotechnology Letters · doi:10.1007/s10529-020-02886-1 · Cited by 50
Menduti, G., Rasà, D. M., Stanga, S., & Boido, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.592234 · Cited by 41
“…SMA-specific DS and DR studies concerning such hormone-based therapies still seem to be promising, as suggested by different works on SMA models reporting the benefits of their administration and recommending further related screenings (Kato et al., 2009; Ohuchi et al., 2016; Wadman et al., 2020).”
BackgroundTakeuchi, H., Inagaki, S., Morozumi, W., Nakano, Y., Inoue, Y., Kuse, Y., Mizoguchi, T., Nakamura, S., Funato, M., Kaneko, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34585-3 · Cited by 37
Self-citationAstrogliosis in multiple sclerosis and neuro-inflammation: what role for the notch pathway?
Mora, P., & Chapouly, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1254586 · Cited by 35
Notch Signaling Mediates Astrocyte Abnormality in Spinal Muscular Atrophy Model Systems
Ohuchi, K., Funato, M., Yoshino, Y., Ando, S., Inagaki, S., Sato, A., Kawase, C., Seki, J., Saito, T., Nishio, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-39788-w · Cited by 33
Self-citationThe Protective Effects of Levetiracetam on a Human iPSCs-Derived Spinal Muscular Atrophy Model
Ando, S., Funato, M., Ohuchi, K., Inagaki, S., Sato, A., Seki, J., Kawase, C., Saito, T., Nishio, H., Nakamura, S., et al. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02814-4 · Cited by 31
Self-citationAndo, S., Funato, M., Ohuchi, K., Kameyama, T., Inagaki, S., Seki, J., Kawase, C., Tsuruma, K., Shimazawa, M., Kaneko, H., et al. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.08.005 · Cited by 28
Self-citationCell reprogramming: methods, mechanisms and applications
Zhu, F., & Nie, G. (2025) · Cell Regeneration · doi:10.1186/s13619-025-00229-x · Cited by 27
Impairment of oligodendrocyte lineages in spinal muscular atrophy model systems
Ohuchi, K., Funato, M., Ando, S., Inagaki, S., Sato, A., Kawase, C., Seki, J., Nakamura, S., Shimazawa, M., Kaneko, H., et al. (2019) · Neuroreport · doi:10.1097/wnr.0000000000001206 · Cited by 21
Self-citationSpinal Muscular Atrophy Modeling and Treatment Advances by Induced Pluripotent Stem Cells Studies
Adami, R., & Bottai, D. (2019) · Stem Cell Reviews and Reports · doi:10.1007/s12015-019-09910-6 · Cited by 19
“Astrocytes activation TRH analogs treatment TRH analog increases the SMN protein level expression by inhibiting GSK3β activity [142]”
BackgroundMethodInfluentialSon, Y. S., Choi, K., Lee, H., Kwon, O., Jung, K. B., Cho, S., Baek, J., Son, B., Kang, S., Kang, M.-G., et al. (2019) · Stem Cells and Development · doi:10.1089/scd.2018.0181 · Cited by 17
Drug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology
Wang, Y., Xu, C., Ma, L., Mou, Y., Zhang, B., Zhou, S., Tian, Y., Trinh, J., Zhang, X., & Li, X.-J. (2019) · Life Science Alliance · doi:10.26508/lsa.201800268 · Cited by 18
Current Development of iPSC-Based Modeling in Neurodegenerative Diseases
Guo, X., Wang, X., Wang, J., Ma, M., & Ren, Q. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083774 · Cited by 17
“Additionally, rarer forms of PD, such as those caused by GBA1 and VPS35 mutations, exhibit similar pathological phenotypes, including α -synuclein accumulation, mitochondrial damage, and elevated ROS production in DA neurons [105,187,188].”
Inagaki, S., Kawase, K., Funato, M., Seki, J., Kawase, C., Ohuchi, K., Kameyama, T., Ando, S., Sato, A., Morozumi, W., et al. (2020) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22975 · Cited by 13
Self-citationRetractedNarmada, B. C., Goh, Y. T., Li, H., Sinha, S., Yu, H., & Cheung, C. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2016-0129 · Cited by 11
SMN Protein Contributes to Skeletal Muscle Cell Maturation Via Caspase-3 and Akt Activation
Ando, S., Tanaka, M., Chinen, N., Nakamura, S., Shimazawa, M., & Hara, H. (2020) · In Vivo · doi:10.21873/invivo.12161 · Cited by 11
Self-citationVulnerability of Purkinje Cells Generated from Spinocerebellar Ataxia Type 6 Patient-Derived iPSCs
Yoshihito, I., Kawakami, H., Kitajima, H., Nishiyama, A., Sasai, Y., Inoue, H., & Muguruma, K. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.012 · Cited by 10
Sierra-Delgado, J. A., Ray, S. S., Kaleem, A., Ganjibakhsh, M., Parvate, M., Powers, S., Zhang, X., Likhite, S. B., & Meyer, K. (2023) · Biology · doi:10.3390/biology12060867 · Cited by 10
Stem cell therapy: A promising therapeutic approach for skeletal muscle atrophy
Wang, Y., Chen, Z., Shen, Y., Wang, K., Han, Y.-M., Zhang, C., Yang, X.-M., & Chen, B. (2025) · World Journal of Stem Cells · doi:10.4252/wjsc.v17.i2.98693 · Cited by 8
“Furthermore, iPSCs mitigate the risk of immune rejection, as they avoid allogeneic transplantation issues[92,93].”
Advances in iPSC Technology in Neural Disease Modeling, Drug Screening, and Therapy
Dai, S., Qiu, L., Veeraraghavan, V. P., Sheu, C., & Mony, U. (2023) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x18666230608105703 · Cited by 9
SMN2 as a therapeutic target in spinal muscular atrophy: advances in gene expression modulation
Virata, M. J., Abello, R. M. R., Brillante, E. M. B., & Corneta, M. B. (2025) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2025.56 · Cited by 7
Investigations of Microtubule-associated Protein 2 Gene Expression in Spinal Muscular Atrophy
Bora, G., Sucularlı, C., Hensel, N., Claus, P., & Erdem‐Yurter, H. (2019) · The Journal of Pediatric Research · doi:10.4274/jpr.galenos.2019.71473 · Cited by 6
“149 maturation in model systems and also patient samples (7-11).”
BackgroundThe Evolution of Stem Cells, Disease Modeling, and Drug Discovery for Neurological Disorders
Pernia, C. D., Tobe, B. T. D., O'Donnell, R., & Snyder, E. Y. (2020) · Stem Cells and Development · doi:10.1089/scd.2019.0217 · Cited by 4
Intellectual disability and abnormal cortical neuron phenotypes in patients with Bloom syndrome
Kaneko, H., Kawase, C., Seki, J., Ikawa, Y., Yachie, A., & Funato, M. (2023) · Journal of Human Genetics · doi:10.1038/s10038-023-01121-9 · Cited by 2
“Thereafter, iPSCs were generated via electroporation with the episomal vector reprogramming factors (OCT3/4, SOX2, KLF4, LIN28, L-MYC, and p53 shRNA) [16, 17]; the procedure was performed using a Nucleofector II Device (Lonza, Basel, Switzerland).”
MethodSelf-citationStem Cells for Modeling Human Disease
Martín, F., Sánchez‐Gilabert, A., Tristán‐Manzano, M., & Benabdellah, K. (2016) · InTech eBooks · doi:10.5772/63231 · Cited by 4
New quantitative method for evaluation of motor functions applicable to spinal muscular atrophy
Matsumaru, N., Hattori, R., Ichinomiya, T., Tsukamoto, K., & Kato, Z. (2018) · Brain and Development · doi:10.1016/j.braindev.2017.12.003 · Cited by 1
Self-citationInduced pluripotent stem cells for modeling of spinal muscular atrophy
Welby, E., & Ebert, A. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85764-2.00010-7 · Cited by 1
Dong, Y., & Watson, D. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.11.687668 · Cited by 1
[Research progress of induced pluripotent stem cells in treatment of muscle atrophy].
Yao, Z., Yang, C., & Sun, G. (2016) · PubMed Central · doi:10.3785/j.issn.1008-9292.2016.03.07
The Effects of Rufinamide on in Vitro Spinal Muscular Atrophy Model
Ando, S., Sato, A., Funato, M., Ohuchi, K., Inagaki, S., Nakamura, S., Shimazawa, M., Kaneko, H., & Hara, H. (2019) · Pharmacology & Pharmacy · doi:10.4236/pp.2019.104014
“The SMN primer sequences were described in the previous report [13].”
BackgroundSelf-citationDLL4 au niveau de la GLIA LIMITANS, un acteur clé de la physiopathologie de la neuro-inflammation
Mora, P. (2023) · theses.fr (ABES) · doi:10.70675/12c7960cz2b86z43f6zb0a8zaedf64fd4cbe
脊髄性筋萎縮症患者の運動機能を定量的に評価する新規指標の開発
松丸, 直., & マツマル, ナ. (2018) · Institutional Repositories DataBase (IRDB)
Metadata
- Authors
- Ohuchi, K., Funato, M., Kato, Z., Seki, J., Kawase, C., Tamai, Y., Ono, Y., Nagahara, Y., Noda, Y., Kameyama, T., Ando, S., Tsuruma, K., Shimazawa, M., Hara, H., & Kaneko, H.
- Affiliations
- Gifu Pharmaceutical University (JP)
- Nagara Medical Center (JP)
- Gifu University (JP)
- Corresponding author
- Funato, Michinori
- ORCID
- Venue
- Stem Cells Translational Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-12-18
- Volume
- 5
- Issue
- 2
- Pages
- 152-163
- ISSN
- 2157-6564 (ISSN-L)
- 2157-6580
- PMC
- PMC4729546
- OpenAlex
- W2207092742
- Cited by
- 34
- References
- 41
- Citations by year
- 2025: 5 · 2023: 4 · 2022: 1 · 2021: 1 · 2020: 5 · 2019: 9 · 2018: 3 · 2017: 1 · 2016: 5
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Stem Cells Translational Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Takeda Science Foundation
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- spinal muscular atrophy, induced pluripotent stem cells, thyrotropin-releasing hormone analog, SMN1, SMN2, glycogen synthase kinase-3β, motor neuron differentiation, axon elongation, dendrite formation, astrocytes, drug screening, platelet-derived growth factor
- MeSH terms
- Glycogen Synthase Kinase 3 beta, Astrocytes, Cell Differentiation, Child, Preschool, Female, Fibroblasts, Humans, Models, Biological, Motor Neurons, Muscular Atrophy, Spinal, Skin, Spine, Thyrotropin-Releasing Hormone, Signal Transduction, Transcriptional Activation, Gene Expression, Apoptosis, Glycogen Synthase Kinase 3, Survival of Motor Neuron 1 Protein, Survival of Motor Neuron 2 Protein, Induced Pluripotent Stem Cells, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.